# Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

> **NCT00606879** · PHASE1 · TERMINATED · sponsor: **SGX Pharmaceuticals, Inc.** · enrollment: 46 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** SGX523 Capsules

## Key facts

- **NCT ID:** NCT00606879
- **Lead sponsor:** SGX Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-06
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2008-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606879, "Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00606879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*